BCM
FLACW

Bluefin Capital Management’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

Bluefin Capital Management’s Portfolio FLACW Stock Details FLACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21,322
Closed -$2K – 751
2022
Q2 		$2K Sell
21,322
-1,007
-5% -$175 ﹤0.01% 564
2022
Q1 		$4K Buy
22,329
+221
+1% +$96 ﹤0.01% 619
2021
Q4 		$13K Buy
+22,108
New +$15.4K ﹤0.01% 789

Other funds holding FLACW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Bluefin Capital Management's FLACW Position: Q3 2022 in Review

Bluefin Capital Management sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q3 2022, closing a stake of 21,322 shares — an estimated $2K sold.

Bluefin Capital Management first reported a position in FLACW in Q4 2021 and held it in 3 quarters. The position peaked at $13K in Q4 2021. 21 funds tracked by Wall St. Rank hold FLACW as of Q3 2022.

  • Bluefin Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q3 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 21,322 Frazier Lifesciences Acquisition Corporation Warrant shares in Q3 2022, an estimated $2K.
  • Bluefin Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q4 2021 and held it in 3 quarters.
  • Bluefin Capital Management's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $13K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q3 2022.

Based on Bluefin Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.